Lilly has launched what it describes as the most powerful Artificial Intelligence factory wholly owned and operated by a pharmaceutical company, designed to help its scientific and development teams pursue medical advancements faster, more accurately and at unprecedented scale. The new platform is intended to integrate advanced computing with drug discovery workflows so researchers can explore larger datasets, iterate on hypotheses more quickly and refine potential therapeutic candidates with greater precision.
The Artificial Intelligence factory, named LillyPod, is built on the world’s first Nvidia DGX SuperPOD with DGX B300 systems, aligning high performance computing infrastructure with specialized Artificial Intelligence hardware. By centralizing this capability, Lilly aims to support a range of activities across discovery and development, from target identification and molecular design to optimization and analysis, while providing consistent tools and resources to internal teams.
Lilly positions LillyPod as a strategic investment in scaling Artificial Intelligence across its pipeline, with the goal of compressing timelines and improving decision quality throughout pharmaceutical research and development. The combination of a dedicated Artificial Intelligence factory and Nvidia DGX SuperPOD architecture is expected to give Lilly a stronger foundation for handling complex models and large volumes of biomedical data in pursuit of new medicines.
